173 related articles for article (PubMed ID: 34282496)
1. Pilot study to determine the safety and feasibility of deceased donor liver natural killer cell infusion to liver transplant recipients with hepatocellular carcinoma.
Ohira M; Hotta R; Tanaka Y; Matsuura T; Tekin A; Selvaggi G; Vianna R; Ricordi C; Ruiz P; Nishida S; Tzakis AG; Ohdan H
Cancer Immunol Immunother; 2022 Mar; 71(3):589-599. PubMed ID: 34282496
[TBL] [Abstract][Full Text] [Related]
2. Clinical-scale isolation of interleukin-2-stimulated liver natural killer cells for treatment of liver transplantation with hepatocellular carcinoma.
Ohira M; Nishida S; Tryphonopoulos P; Tekin A; Selvaggi G; Moon J; Levi D; Ricordi C; Ishiyama K; Tanaka Y; Ohdan H; Tzakis AG
Cell Transplant; 2012; 21(7):1397-406. PubMed ID: 22469170
[TBL] [Abstract][Full Text] [Related]
3. Liver natural killer cell inoculum for liver transplantation with hepatocellular carcinoma.
Nishida S; Levi DM; Tzakis AG
Curr Opin Organ Transplant; 2013 Dec; 18(6):690-4. PubMed ID: 24220052
[TBL] [Abstract][Full Text] [Related]
4. Adoptive transfer of TRAIL-expressing natural killer cells prevents recurrence of hepatocellular carcinoma after partial hepatectomy.
Ohira M; Ohdan H; Mitsuta H; Ishiyama K; Tanaka Y; Igarashi Y; Asahara T
Transplantation; 2006 Dec; 82(12):1712-9. PubMed ID: 17198265
[TBL] [Abstract][Full Text] [Related]
5. Donor Age Correlates With Liver-Resident Natural Killer Cell Activity in Adoptive Immunotherapy Using Donor Liver Natural Killer Cells in Liver Transplantation.
Ohira M; Imaoka K; Bekki T; Sato K; Imaoka Y; Nakano R; Yano T; Doskali M; Shimizu S; Chogahara I; Sato S; Nakamura M; Tanaka Y; Ohdan H
Transplant Proc; 2024 Apr; 56(3):667-671. PubMed ID: 38326202
[TBL] [Abstract][Full Text] [Related]
6. Adoptive Transfer of Autologous Invariant Natural Killer T Cells as Immunotherapy for Advanced Hepatocellular Carcinoma: A Phase I Clinical Trial.
Gao Y; Guo J; Bao X; Xiong F; Ma Y; Tan B; Yu L; Zhao Y; Lu J
Oncologist; 2021 Nov; 26(11):e1919-e1930. PubMed ID: 34255901
[TBL] [Abstract][Full Text] [Related]
7. Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in humans.
Ishiyama K; Ohdan H; Ohira M; Mitsuta H; Arihiro K; Asahara T
Hepatology; 2006 Feb; 43(2):362-72. PubMed ID: 16440347
[TBL] [Abstract][Full Text] [Related]
8. Liver Perfusate Natural Killer Cells From Deceased Brain Donors and Association With Acute Cellular Rejection After Liver Transplantation: A Time-to-Rejection Analysis.
Pagano D; Badami E; Conaldi PG; Seidita A; Tuzzolino F; Barbàra M; di Francesco F; Tropea A; Liotta R; Chiarello G; Luca A; Gruttadauria S
Transplantation; 2019 Feb; 103(2):371-380. PubMed ID: 29912045
[TBL] [Abstract][Full Text] [Related]
9. A Phase I Study of Locoregional High-Dose Autologous Natural Killer Cell Therapy With Hepatic Arterial Infusion Chemotherapy in Patients With Locally Advanced Hepatocellular Carcinoma.
Bae WK; Lee BC; Kim HJ; Lee JJ; Chung IJ; Cho SB; Koh YS
Front Immunol; 2022; 13():879452. PubMed ID: 35720374
[TBL] [Abstract][Full Text] [Related]
10. Impact of KIR-HLA Genotype on Natural-Killer-Cell-Based Immunotherapy for Preventing Hepatocellular Carcinoma after Living-Donor Liver Transplantation.
Tanimine N; Ohira M; Kurita E; Nakano R; Sakai H; Tahara H; Ide K; Kobayashi T; Tanaka Y; Ohdan H
Cancers (Basel); 2024 Jan; 16(3):. PubMed ID: 38339284
[TBL] [Abstract][Full Text] [Related]
11. Incidence and risk factors of hepatocellular carcinoma recurrence after liver transplantation in the MELD era.
Sharma P; Welch K; Hussain H; Pelletier SJ; Fontana RJ; Marrero J; Merion RM
Dig Dis Sci; 2012 Mar; 57(3):806-12. PubMed ID: 21953139
[TBL] [Abstract][Full Text] [Related]
12. Expanded and Activated Natural Killer Cells for Immunotherapy of Hepatocellular Carcinoma.
Kamiya T; Chang YH; Campana D
Cancer Immunol Res; 2016 Jul; 4(7):574-81. PubMed ID: 27197065
[TBL] [Abstract][Full Text] [Related]
13. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
[TBL] [Abstract][Full Text] [Related]
14. MRI-guided interventional natural killer cell delivery for liver tumor treatment.
Su Z; Wang X; Zheng L; Lyu T; Figini M; Wang B; Procissi D; Shangguan J; Sun C; Pan L; Qin L; Zhang B; Velichko Y; Salem R; Yaghmai V; Larson AC; Zhang Z
Cancer Med; 2018 May; 7(5):1860-1869. PubMed ID: 29601672
[TBL] [Abstract][Full Text] [Related]
15. The stratifying value of Hangzhou criteria in liver transplantation for hepatocellular carcinoma.
Chen J; Xu X; Wu J; Ling Q; Wang K; Wang W; Zhang M; Shen Y; Zhou L; Xie H; Zheng S
PLoS One; 2014; 9(3):e93128. PubMed ID: 24676010
[TBL] [Abstract][Full Text] [Related]
16. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis.
Kulik L; Heimbach JK; Zaiem F; Almasri J; Prokop LJ; Wang Z; Murad MH; Mohammed K
Hepatology; 2018 Jan; 67(1):381-400. PubMed ID: 28859222
[TBL] [Abstract][Full Text] [Related]
17. Liver transplantation for hepatocellular carcinoma within the Milan criteria versus the University of California San Francisco criteria: a comparative study.
Abdelfattah MR; Elsiesy H; Al-Manea H; Broering DC
Eur J Gastroenterol Hepatol; 2018 Apr; 30(4):398-403. PubMed ID: 29280920
[TBL] [Abstract][Full Text] [Related]
18. Complete pathologic response to pretransplant locoregional therapy for hepatocellular carcinoma defines cancer cure after liver transplantation: analysis of 501 consecutively treated patients.
Agopian VG; Morshedi MM; McWilliams J; Harlander-Locke MP; Markovic D; Zarrinpar A; Kaldas FM; Farmer DG; Yersiz H; Hiatt JR; Busuttil RW
Ann Surg; 2015 Sep; 262(3):536-45; discussion 543-5. PubMed ID: 26258323
[TBL] [Abstract][Full Text] [Related]
19. Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy.
Sun C; Sun HY; Xiao WH; Zhang C; Tian ZG
Acta Pharmacol Sin; 2015 Oct; 36(10):1191-9. PubMed ID: 26073325
[TBL] [Abstract][Full Text] [Related]
20. Donor Polymorphisms of Toll-like Receptor 4 rs1927914 Associated with the Risk of Hepatocellular Carcinoma Recurrence Following Liver Transplantation.
Shi G; Wang C; Zhang P; Ji L; Xu S; Tan X; Li H
Arch Med Res; 2017 Aug; 48(6):553-560. PubMed ID: 29221801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
